EI
OLMA icon

EAM Investors’s Olema Pharmaceuticals OLMA Stock Holding History

EAM Investors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-228,139
Closed -$3.2M – 311
2023
Q4 		$3.2M Sell
228,139
-15,151
-6% -$204K 0.57% 98
2023
Q3 		$3M Buy
243,290
+73,560
+43% +$750K 0.58% 30
2023
Q2 		$1.53M Buy
+169,730
New +$1.02M 0.28% 173

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

EAM Investors's OLMA Position: Q1 2024 in Review

EAM Investors sold out of Olema Pharmaceuticals (OLMA) in Q1 2024, closing a stake of 228,139 shares — an estimated $3.2M sold.

EAM Investors first reported a position in OLMA in Q2 2023 and held it in 3 quarters. The position peaked at $3.2M in Q4 2023. 126 funds tracked by Wall St. Rank hold OLMA as of Q1 2024.

  • EAM Investors reported no remaining Olema Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • EAM Investors sold 228,139 Olema Pharmaceuticals shares in Q1 2024, an estimated $3.2M.
  • EAM Investors first reported a position in Olema Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • EAM Investors's Olema Pharmaceuticals position peaked at $3.2M in Q4 2023.
  • 126 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2024.

Based on EAM Investors's 13F filing for Q1 2024, filed 13 May 2024.